GC 1118A

Drug Profile

GC 1118A

Alternative Names: Anti-EGFR monoclonal antibody-Green Cross; GC 1118; GC1118A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastric cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Second-line therapy or greater) in South Korea (IV, Infusion)
  • 01 Jan 2015 Phase-I clinical trials in Gastric cancer and Colorectal cancer (Late-stage disease, Second-line therapy or greater) in South Korea (IV) (NCT02352571)
  • 05 May 2014 Phase-I clinical trials in Colorectal cancer in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top